GLP-1 substitutes are taking shape.
The news: Telemedicine startup Twin Health added $50M in a Series D round. Leveraging machine learning, the company creates digital patient avatars, predicting effective lifestyle interventions for metabolic disease reversal.
Combining quarterly labs, 1:1 virtual care, at-home biometrics monitoring, and AI-powered recommendations, it offers an alternative to obesity drugs.
Behavior change 2.0. GLP-1s are here to stay, but cost, supply, and long-term effects remain concerning. Balancing the scales, telehealth startups are making a new case for behavioral approaches.
- Following a successful trial, holistic care company Love.Life and longevity science startup L-Nutra launched clinical fasting-mimicking programs for diabetes reversal.
- Targeting employers, Virta Health claims its keto-based nutritional therapy programs can eliminate drug dependency in six months.
- Also touting digital twins, CGM-enabled January AI published a study showing wearables’ potential to improve metabolic biomarkers and promote weight loss.
Shifting away from willpower, digital health interventions are acknowledging genetics’ influence on weight — combining continuous biometric screening, AI-driven insights, and provider-led care plans for better outcomes.
Precision nutrition. Adjacent to obesity management, healthcare is slowly embracing food-as-medicine.
Adding $7M this month, Season Health pairs members with dietitians to prescribe medically tailored meals for everything from hypertension to high-risk pregnancy.
Punchline: Telling people to diet doesn’t work, but relying on GLP-1s alone won’t fix root causes of the obesity epidemic. Whether as an alternative, complement, or continuation of care, behavior change remains crucial to the metabolic health conversation.